Duke University Medical Center to Assess Probiotics in COVID-19 Exposure
Retrieved on:
Tuesday, June 2, 2020
Household exposure to SARS-CoV-2 is thought to result in up to >20-fold increased risk of infection.
Key Points:
- Household exposure to SARS-CoV-2 is thought to result in up to >20-fold increased risk of infection.
- The trial will specifically study and utilize the commercial probiotic, Culturelle, delivering Lactobacillus rhamnosus GG, in household contacts at high risk for COVID-19.
- These benefits may be mediated by the beneficial effects of probiotics on the immune system.
- These clinical and immunomodulatory benefits are especially relevant to individuals who have developed or are at risk of developing COVID-19.